Cargando…
A Potential Long-Acting LDL-Cholesterol–Lowering PCSK9 Monoclonal Antibody: Randomized, Placebo-Controlled Phase 1 Studies
The aim of the studies was to evaluate the safety, tolerability, and efficacy of tafolecimab, a novel proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibody, in Chinese healthy volunteers and patients with hypercholesterolemia. Fifty-eight healthy volunteers (phase 1a) were random...
| Autores principales: | , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9627834/ https://www.ncbi.nlm.nih.gov/pubmed/36341216 http://dx.doi.org/10.1016/j.jacasi.2021.09.002 |